Catalyst Pharmaceuticals (CPRX) EBT Margin (2018 - 2026)
Catalyst Pharmaceuticals posted quarterly EBT Margin of 56.38% for Q1 2026, up 598.0% year-on-year from 8.08% in Q1 2025, and up 19.67% on a QoQ basis from 47.11% in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 9 years of EBT Margin data on file, last reported at 56.38% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 598.0% year-over-year to 56.38%; the trailing twelve-month figure through Mar 2026 stood at 49.66% (up 132.0% YoY), and the FY2025 full-year result was 48.14%, up 416.0% from the prior year.
- EBT Margin for Q1 2026 stood at 56.38%, up from 47.11% in the prior quarter.
- Across five years, EBT Margin topped out at 56.38% in Q1 2026 and bottomed at 37.03% in Q3 2023.
- The 5-year median for EBT Margin is 47.11% (2025), against an average of 41.88%.
- The widest annual swing landed in 2023, when EBT Margin tumbled 8246 bps; it then soared 8148 bps in 2024.
- A 5-year view of EBT Margin shows it stood at 54.33% in 2022, then decreased by 22 bps to 42.24% in 2023, then grew by 24 bps to 52.31% in 2024, then fell by 10 bps to 47.11% in 2025, then gained by 20 bps to 56.38% in 2026.
- The last three EBT Margin figures came in at 56.38% (Q1 2026), 47.11% (Q4 2025), and 47.87% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 18.99% |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn | 56.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 56.38% |
| Dec 31, 2025 | 47.11% |
| Sep 30, 2025 | 47.87% |
| Jun 30, 2025 | 47.28% |
| Mar 31, 2025 | 50.41% |
| Dec 31, 2024 | 52.31% |
| Sep 30, 2024 | 44.45% |
| Jun 30, 2024 | 45.46% |
| Mar 31, 2024 | 29.53% |
| Dec 31, 2023 | 42.24% |
| Sep 30, 2023 | -37.03% |
| Jun 30, 2023 | 48.72% |
| Mar 31, 2023 | 43.71% |
| Dec 31, 2022 | 54.33% |
| Sep 30, 2022 | 45.43% |
| Jun 30, 2022 | 53.18% |
| Mar 31, 2022 | 40.52% |
| Dec 31, 2021 | 33.45% |
| Sep 30, 2021 | 39.14% |
| Jun 30, 2021 | 43.72% |
| Mar 31, 2021 | 32.72% |
| Dec 31, 2020 | 28.13% |
| Sep 30, 2020 | 40.03% |
| Jun 30, 2020 | 35.11% |
| Mar 31, 2020 | 37.88% |
| Dec 31, 2019 | 27.90% |
| Sep 30, 2019 | 46.08% |
| Jun 30, 2019 | 39.56% |
| Mar 31, 2019 | -5.18% |
| Dec 31, 2018 | -2,899.92% |